Clinical Trials · NCT00088595
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 45
- Start date
- Jan 2004
- Locations
- 4 sites, United States
- Primary endpoint
- Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary